ERBB2 and breast cancer: The APHINITY trial was a phase III study that demonstrated that adjuvant pertuzumab, in combination with trastuzumab and chemotherapy, significantly improved invasive disease-free survival (iDFS) among patients with operable HER2-positive BC [27,36].